Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 130, Issue 4, Pages 1576-1585Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI129206
Keywords
-
Categories
Ask authors/readers for more resources
Lymphoid malignancies typically promote an infiltrate of immune cells at sites involved by the disease. While some of the immune cells present in lymphoma have effector function, the immune system is unable to eradicate the malignant clone. Therapies that optimize immune function therefore have the potential to improve the outcome of lymphoma patients. In this Review, we discuss immunologic approaches that directly target the malignant cell as well as approaches to optimize both the innate and adaptive immune response to the tumor. While many of these therapies have shown single-agent activity, the future will clearly require thoughtful combinations of these approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available